Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins FLT3 N676K||acute myeloid leukemia||predicted - resistant||Midostaurin||Case Reports/Case Series||Actionable||In a clinical case study, a patient with acute myeloid leukemia harboring a FLT3-ITD mutation progressed on Rydapt (midostaurin) after 288 days and was found to have acquired a FLT3 N676K mutation, and resistance was also confirmed in patient-derived cells in culture (PMID: 16150941).||16150941|
|FLT3 exon 14 ins FLT3 N676K||acute myeloid leukemia||predicted - resistant||Pexidartinib||Case Reports/Case Series||Actionable||In a Phase I/II trial, an acute myeloid leukemia patient harboring a FLT3-ITD was found to have acquired FLT3 N676K following relapse on Turalio (pexidartinib) treatment (PMID: 34103301; NCT01349049).||34103301|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|